Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Sonnet BioTherapeutics Holdings Inc (Sonnet), formerly Chanticleer Holdings Inc, is an oncology-biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific, bifunctional action. The company’s pipeline program includes Son-1010(IL12-FHAB), Son-1210(IL12-FHAB), Son-1210(IL12-FHAB-1L15), Son-1410(IL18-FHAB-1L12), Son-3015(Anti-1L6-FHAB-Anti-TGFB), SON-080(Low-dose IL- 6). Its pipeline candidates treat solid tumors, platinum-resistant ovarian cancer, solid tumors, melanoma renal cancers, tumor and bone metastases, chemotherapy-induced peripheral neurotherapy and diabetic peripheral neuropathy. Sonnet harnesses its proprietary FHAB (Fully Human Albumin Binding) technology to discover biologic drugs with single or bispecific action for antiviral applications. Its FHAB platform also serves as a plug-and-play construct for enhancing the potential of a broad range of large molecule therapeutic classes, including peptides, antibodies, cytokines, and vaccines. Sonnet is headquartered in Princeton, New Jersey, the US.
Headquarters
United States of America
Address
100 Overlook Center, Suite 102, Princeton, New Jersey, 08540
Website
www.sonnetbio.com
Telephone
1 609 3752227
No of Employees
12
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SONN (NASD)
Revenue (2022)
$147,800
-57.8%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
36.6%
(2022 vs 2021)
Market Cap*
$4.9M
Net Profit Margin (2022)
XYZ
-50.0%
(2022 vs 2021)
* As of and is in US$
Products and Services
| Products |
|---|
| Pipeline: |
| Son-1010(IL12-FHAB) : Solid Tumors |
| Son-1210(IL12-FHAB): Platinum-Resistant Ovarian Cancer |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Sonnet BioTherapeutics Holdings Inc | Collegium Pharmaceutical Inc | Northwest Biotherapeutics Inc | Inovio Pharmaceuticals Inc | Intellipharmaceutics International Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | Canada |
| City | Princeton | Stoughton | Bethesda | Plymouth Meeting | Etobicoke |
| State/Province | New Jersey | Massachusetts | Maryland | Pennsylvania | Ontario |
| No. of Employees | 12 | 197 | 25 | 122 | 33 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Pankaj Mohan, Ph.D. | Chairman; Chief Executive Officer | Executive Board | 2020 | 59 |
| Jay Cross | Chief Financial Officer | Senior Management | 2020 | 52 |
| Richard Kenney, M.D | Chief Medical Officer | Senior Management | 2021 | 65 |
| John K. Cini, Ph.D. | Chief Scientific Officer | Senior Management | 2020 | 71 |
| Susan Dexter | Chief Technical Officer | Senior Management | 2020 | 67 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer